Cargando…

Molecular clones of genetically distinct hepatitis B virus genotypes reveal distinct host and drug treatment responses

BACKGROUND & AIMS: HBV exhibits wide genetic diversity with at least 9 genotypes (GTs), which differ in terms of prevalence, geographic distribution, natural history, disease progression, and treatment outcome. However, differences in HBV replicative capacity, gene expression, and infective capa...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yongzhen, Park, Debby, Cafiero, Thomas R., Bram, Yaron, Chandar, Vasuretha, Tseng, Anna, Gertje, Hans P., Crossland, Nicholas A., Su, Lishan, Schwartz, Robert E., Ploss, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403497/
https://www.ncbi.nlm.nih.gov/pubmed/36035359
http://dx.doi.org/10.1016/j.jhepr.2022.100535
_version_ 1784773390906687488
author Liu, Yongzhen
Park, Debby
Cafiero, Thomas R.
Bram, Yaron
Chandar, Vasuretha
Tseng, Anna
Gertje, Hans P.
Crossland, Nicholas A.
Su, Lishan
Schwartz, Robert E.
Ploss, Alexander
author_facet Liu, Yongzhen
Park, Debby
Cafiero, Thomas R.
Bram, Yaron
Chandar, Vasuretha
Tseng, Anna
Gertje, Hans P.
Crossland, Nicholas A.
Su, Lishan
Schwartz, Robert E.
Ploss, Alexander
author_sort Liu, Yongzhen
collection PubMed
description BACKGROUND & AIMS: HBV exhibits wide genetic diversity with at least 9 genotypes (GTs), which differ in terms of prevalence, geographic distribution, natural history, disease progression, and treatment outcome. However, differences in HBV replicative capacity, gene expression, and infective capability across different GTs remain incompletely understood. Herein, we aimed to study these crucial aspects using newly constructed infectious clones covering the major HBV GTs. METHODS: The replicative capacity of infectious clones covering HBV GTs A-E was analyzed in cell lines, primary hepatocytes and humanized mice. Host responses and histopathology induced by the different HBV GTs were characterized in hydrodynamically injected mice. Differences in treatment responses to entecavir and various HBV capsid inhibitors were also quantified across the different genetically defined GTs. RESULTS: Patient-derived HBV infectious clones replicated robustly both in vitro and in vivo. GTs A and D induce more pronounced intrahepatic and proinflammatory cytokine responses which correlated with faster viral clearance. Notably, all 5 HBV clones robustly produced viral particles following transfection into HepG2 cells, and these particles were infectious in HepG2-NTCP cells, primary human hepatocytes and human chimeric mice. Notably, GT D virus exhibited higher infectivity than GTs A, B, C and E in vitro, although it was comparable to GT A and B in the human liver chimeric mice in vivo. HBV capsid inhibitors were more readily capable of suppressing HBV GTs A, B, D and E than C. CONCLUSIONS: The infectious clones described here have broad utility as genetic tools that can mechanistically dissect intergenotypic differences in antiviral immunity and pathogenesis and aid in HBV drug development and screening. LAY SUMMARY: The hepatitis B virus (HBV) is a major contributor to human morbidity and mortality. HBV can be categorized into a number of genotypes, based on their specific genetic make-up, of which 9 are well known. We isolated and cloned the genomes of 5 of these genotypes and used them to create valuable tools for future research on this clinically important virus.
format Online
Article
Text
id pubmed-9403497
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-94034972022-08-26 Molecular clones of genetically distinct hepatitis B virus genotypes reveal distinct host and drug treatment responses Liu, Yongzhen Park, Debby Cafiero, Thomas R. Bram, Yaron Chandar, Vasuretha Tseng, Anna Gertje, Hans P. Crossland, Nicholas A. Su, Lishan Schwartz, Robert E. Ploss, Alexander JHEP Rep Research Article BACKGROUND & AIMS: HBV exhibits wide genetic diversity with at least 9 genotypes (GTs), which differ in terms of prevalence, geographic distribution, natural history, disease progression, and treatment outcome. However, differences in HBV replicative capacity, gene expression, and infective capability across different GTs remain incompletely understood. Herein, we aimed to study these crucial aspects using newly constructed infectious clones covering the major HBV GTs. METHODS: The replicative capacity of infectious clones covering HBV GTs A-E was analyzed in cell lines, primary hepatocytes and humanized mice. Host responses and histopathology induced by the different HBV GTs were characterized in hydrodynamically injected mice. Differences in treatment responses to entecavir and various HBV capsid inhibitors were also quantified across the different genetically defined GTs. RESULTS: Patient-derived HBV infectious clones replicated robustly both in vitro and in vivo. GTs A and D induce more pronounced intrahepatic and proinflammatory cytokine responses which correlated with faster viral clearance. Notably, all 5 HBV clones robustly produced viral particles following transfection into HepG2 cells, and these particles were infectious in HepG2-NTCP cells, primary human hepatocytes and human chimeric mice. Notably, GT D virus exhibited higher infectivity than GTs A, B, C and E in vitro, although it was comparable to GT A and B in the human liver chimeric mice in vivo. HBV capsid inhibitors were more readily capable of suppressing HBV GTs A, B, D and E than C. CONCLUSIONS: The infectious clones described here have broad utility as genetic tools that can mechanistically dissect intergenotypic differences in antiviral immunity and pathogenesis and aid in HBV drug development and screening. LAY SUMMARY: The hepatitis B virus (HBV) is a major contributor to human morbidity and mortality. HBV can be categorized into a number of genotypes, based on their specific genetic make-up, of which 9 are well known. We isolated and cloned the genomes of 5 of these genotypes and used them to create valuable tools for future research on this clinically important virus. Elsevier 2022-07-09 /pmc/articles/PMC9403497/ /pubmed/36035359 http://dx.doi.org/10.1016/j.jhepr.2022.100535 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Liu, Yongzhen
Park, Debby
Cafiero, Thomas R.
Bram, Yaron
Chandar, Vasuretha
Tseng, Anna
Gertje, Hans P.
Crossland, Nicholas A.
Su, Lishan
Schwartz, Robert E.
Ploss, Alexander
Molecular clones of genetically distinct hepatitis B virus genotypes reveal distinct host and drug treatment responses
title Molecular clones of genetically distinct hepatitis B virus genotypes reveal distinct host and drug treatment responses
title_full Molecular clones of genetically distinct hepatitis B virus genotypes reveal distinct host and drug treatment responses
title_fullStr Molecular clones of genetically distinct hepatitis B virus genotypes reveal distinct host and drug treatment responses
title_full_unstemmed Molecular clones of genetically distinct hepatitis B virus genotypes reveal distinct host and drug treatment responses
title_short Molecular clones of genetically distinct hepatitis B virus genotypes reveal distinct host and drug treatment responses
title_sort molecular clones of genetically distinct hepatitis b virus genotypes reveal distinct host and drug treatment responses
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403497/
https://www.ncbi.nlm.nih.gov/pubmed/36035359
http://dx.doi.org/10.1016/j.jhepr.2022.100535
work_keys_str_mv AT liuyongzhen molecularclonesofgeneticallydistincthepatitisbvirusgenotypesrevealdistincthostanddrugtreatmentresponses
AT parkdebby molecularclonesofgeneticallydistincthepatitisbvirusgenotypesrevealdistincthostanddrugtreatmentresponses
AT cafierothomasr molecularclonesofgeneticallydistincthepatitisbvirusgenotypesrevealdistincthostanddrugtreatmentresponses
AT bramyaron molecularclonesofgeneticallydistincthepatitisbvirusgenotypesrevealdistincthostanddrugtreatmentresponses
AT chandarvasuretha molecularclonesofgeneticallydistincthepatitisbvirusgenotypesrevealdistincthostanddrugtreatmentresponses
AT tsenganna molecularclonesofgeneticallydistincthepatitisbvirusgenotypesrevealdistincthostanddrugtreatmentresponses
AT gertjehansp molecularclonesofgeneticallydistincthepatitisbvirusgenotypesrevealdistincthostanddrugtreatmentresponses
AT crosslandnicholasa molecularclonesofgeneticallydistincthepatitisbvirusgenotypesrevealdistincthostanddrugtreatmentresponses
AT sulishan molecularclonesofgeneticallydistincthepatitisbvirusgenotypesrevealdistincthostanddrugtreatmentresponses
AT schwartzroberte molecularclonesofgeneticallydistincthepatitisbvirusgenotypesrevealdistincthostanddrugtreatmentresponses
AT plossalexander molecularclonesofgeneticallydistincthepatitisbvirusgenotypesrevealdistincthostanddrugtreatmentresponses